Here's What Medicare Part B Costs in 2026

Medicare Part B costs are rising for 2026 with the standard monthly premium increasing to $202.90 (from $185 in 2025) and the annual deductible rising to $283 (from $257). Higher earners face income-related surcharges above $109,000 (single) or $218,000 (joint); Medigap policies commonly cover the 20% Part B coinsurance (and some older plans may cover the deductible) but do not pay premiums, making enrollment timing and plan selection material for retirees' out-of-pocket exposure.

Analysis

Market structure: A ~9.7% increase in Part B premium (from $185 to $202.90) and ~10.1% rise in the deductible (to $283) re-rates the retiree cost calculus and benefits sellers of Medicare Advantage (UNH, HUM, CVS) and Medigap supplemental policies (large multinationals with Medicare distribution). Higher-income IRMAA thresholds ($109k/$218k) lock in extra revenue for carriers who can cross‑sell supplemental products while pressuring discretionary spending for fixed‑income retirees over the next 12 months.

Competitive dynamics: Expect share gains for vertically integrated players (UNH, CVS/Aetna) that can bundle MA + supplemental offerings and hold pricing power during AEP/initial enrollment windows; smaller regional carriers face adverse selection and must raise Medigap rates, increasing consolidation risk in 2026–2027. Insurers with large Medicare footprints can expand margins via higher per-member premiums and reduced medical loss ratios if utilization remains stable.

Supply/Demand & cross‑asset: Modest outpatient utilization headwinds for discretionary procedures over 3–12 months could depress revenue for elective services and lab diagnostics (DGX, LH), while insurer equities and broker/benefit-advisor fees see upside; expect incremental implied volatility in insurer options around AEP (Oct–Dec). Bond markets: marginally higher retiree drawdowns increase unsecured consumer stress—monitor ABS and muni credit spreads for small widening.

Risk & catalysts: Tail risks include CMS policy intervention or Congressional limits on Part B growth (6–18 months), or faster-than-expected migration into MA/Medigap that compresses new-business margins. Key catalysts: CMS spring rulemaking, Oct–Dec AEP enrollment data, and Q2–Q3 insurer filings; these will accelerate or reverse trends.

Key Decisions for Investors

• Establish a 2–3% long position in UNH (UnitedHealth) within 1–3 months to capture MA and Medigap cross‑sell tailwinds ahead of AEP; target +18–25% upside over 12 months, stop loss 10%.
• Initiate a 1.5–2% long position in HUM (Humana) via a 6–12 month call spread (buy ATM, sell +15–20% OTM) to limit premium and play Medicare Advantage enrollment growth; close post‑AEP (Dec 2026) or on 15% adverse move.
• Enter a pair trade: long UNH (1.5%) / short DGX (Quest Diagnostics) (1%) to express insurer upside vs outpatient diagnostic utilization pressure over next 6–12 months; rebalance after Oct–Dec enrollment results.
• Reduce direct exposure to small/regional Medigap sellers and elective outpatient providers by 25–50% in portfolios tilted to seniors-focused cashflows; redeploy proceeds into large-cap MA insurers or short-dated protection on DGX/LH, monitoring CMS announcements in next 60 days.